Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 1.76
ATRS's Cash-to-Debt is ranked higher than
97% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.55 vs. ATRS: 1.76 )
Ranked among companies with meaningful Cash-to-Debt only.
ATRS' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.01  Med: No Debt Max: No Debt
Current: 1.76
Equity-to-Asset 0.48
ATRS's Equity-to-Asset is ranked higher than
57% of the 184 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.61 vs. ATRS: 0.48 )
Ranked among companies with meaningful Equity-to-Asset only.
ATRS' s Equity-to-Asset Range Over the Past 10 Years
Min: -4.09  Med: 0.62 Max: 0.95
Current: 0.48
-4.09
0.95
Interest Coverage N/A
ATRS's Interest Coverage is ranked higher than
96% of the 135 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 40.83 vs. ATRS: N/A )
Ranked among companies with meaningful Interest Coverage only.
ATRS' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: N/A
Piotroski F-Score: 5
Altman Z-Score: 2.85
Beneish M-Score: -2.97
WACC vs ROIC
4.47%
-96.88%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -33.60
ATRS's Operating Margin % is ranked lower than
81% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.15 vs. ATRS: -33.60 )
Ranked among companies with meaningful Operating Margin % only.
ATRS' s Operating Margin % Range Over the Past 10 Years
Min: -215.47  Med: -75.92 Max: -26.96
Current: -33.6
-215.47
-26.96
Net Margin % -34.27
ATRS's Net Margin % is ranked lower than
81% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.28 vs. ATRS: -34.27 )
Ranked among companies with meaningful Net Margin % only.
ATRS' s Net Margin % Range Over the Past 10 Years
Min: -224.17  Med: -75.04 Max: -26.66
Current: -34.27
-224.17
-26.66
ROE % -39.48
ATRS's ROE % is ranked lower than
81% of the 183 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.37 vs. ATRS: -39.48 )
Ranked among companies with meaningful ROE % only.
ATRS' s ROE % Range Over the Past 10 Years
Min: -127.89  Med: -53.09 Max: -19.42
Current: -39.48
-127.89
-19.42
ROA % -25.08
ATRS's ROA % is ranked lower than
81% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.13 vs. ATRS: -25.08 )
Ranked among companies with meaningful ROA % only.
ATRS' s ROA % Range Over the Past 10 Years
Min: -52.7  Med: -33.9 Max: -15.37
Current: -25.08
-52.7
-15.37
ROC (Joel Greenblatt) % -99.41
ATRS's ROC (Joel Greenblatt) % is ranked lower than
80% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 11.96 vs. ATRS: -99.41 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ATRS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -2034.35  Med: -734.8 Max: -141.9
Current: -99.41
-2034.35
-141.9
3-Year Revenue Growth Rate 27.70
ATRS's 3-Year Revenue Growth Rate is ranked higher than
94% of the 156 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.80 vs. ATRS: 27.70 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ATRS' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -63.5  Med: 10.35 Max: 93.3
Current: 27.7
-63.5
93.3
3-Year EBITDA Growth Rate -3.50
ATRS's 3-Year EBITDA Growth Rate is ranked lower than
65% of the 130 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.80 vs. ATRS: -3.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ATRS' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -41.5  Med: -9.9 Max: 80.8
Current: -3.5
-41.5
80.8
GuruFocus has detected 6 Warning Signs with Antares Pharma Inc $ATRS.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ATRS's 30-Y Financials

Financials (Next Earnings Date: 2017-11-09 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

ATRS Guru Trades in Q3 2016

First Eagle Investment 20,000 sh (unchged)
Chuck Royce 406,900 sh (unchged)
Jim Simons 2,674,341 sh (-1.60%)
» More
Q4 2016

ATRS Guru Trades in Q4 2016

Jim Simons 2,859,341 sh (+6.92%)
First Eagle Investment 20,000 sh (unchged)
Chuck Royce Sold Out
» More
Q1 2017

ATRS Guru Trades in Q1 2017

Louis Moore Bacon 200,000 sh (New)
Jim Simons 3,152,569 sh (+10.26%)
First Eagle Investment 20,000 sh (unchged)
» More
Q2 2017

ATRS Guru Trades in Q2 2017

Jim Simons 3,462,469 sh (+9.83%)
Louis Moore Bacon 200,000 sh (unchged)
First Eagle Investment 20,000 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:ATRS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies    NAICS: 339112    SIC: 3841
Compare:NAS:STAA, NAS:ENTL, NAS:ELGX, NAS:PLSE, NAS:ANGO, NAS:LMAT, NAS:UTMD, NAS:SIEN, NAS:CFMS, NAS:ATRC, NAS:LAKE, NAS:HBIO, NAS:IVTY, AMEX:TRXC, NAS:LMNX, AMEX:BVX, NAS:BLFS, NAS:EKSO, NAS:BIOL, AMEX:INFU » details
Traded in other countries:MJC.Germany,
Headquarter Location:USA
Antares Pharma Inc is a specialty pharmaceutical company. It is engaged in developing and commercializing self-administered parenteral pharmaceutical products and technologies including novel, pressure-assisted injectors.

Antares Pharma Inc was incorporated on January 31, 1979. The Company is a specialty pharmaceutical company. It is engaged in developing and commercializing self-administered parenteral pharmaceutical products and technologies. It develops & manufactures novel, pressure-assisted injectors, with and without needles, which allow patients to self-inject drugs. The Company has developed variations of the needle-free injector by adding a small shielded needle to a pre-filled, single-use disposable injector, called the Vibex pressure assisted auto injection system. This system is an alternative to the needle-free system for use with injectable drugs in unit dose containers and is suitable for branded and generic injectables. It also developed a disposable multi-dose pen injector for use with standard cartridges. The Company developed the Vibex auto injector for its product OTREXUP. The Company has launched OTREXUP injection, subcutaneous methotrexate for once weekly self-administration with an easy-to-use, single dose, disposable auto injector. The Company is conducting clinical studies of Vibex QS T, for testosterone replacement therapy. It is also developing VIBEX Sumatriptan for the acute treatment of migraines. The Company's development projects include VIBEX epinephrine, an exenatide multi-dose pen, and another undisclosed multi-dose pen. The Company also makes a reusable, needle-free, spring-action injector device known as the Tjet and Zomajet, which is marketed for use with human growth hormone. The Company also has a portfolio of gel-based products inclduing Gelnique for the treatment of overactive bladder. The Company sells its proprietary reusable needle-free injectors and related disposable products to pharmaceutical partners and through medical product distributors. The Company's competitors include Pfizer, NovoNordisk, Warner-Chilcott, Novartis, Mylan, Roxane, Bedford Labs, Hospira, and Accord Healthcare. Any potential products discovered, developed and manufactured by the Company must comply with comprehensive regulation by the FDA in the U.S. and by comparable authorities in other countries.

Top Ranked Articles about Antares Pharma Inc

Antares Pharma to Report Second Quarter 2017 Financial and Operating Results and Host Webcast and Conference Call
Antares Pharma Announces Debt Financing From Hercules Capital
Antares Pharma to Present at the Jefferies 2017 Healthcare Conference
Antares Pharma Announces Poster Presentation at the American Urological Association Annual Meeting
Antares Pharma Reports First Quarter 2017 Operating and Financial Results
Antares Pharma to Report First Quarter 2017 Financial and Operating Results and Host Webcast and Conference Call
Antares Pharma to Present at the Deutsche Bank Securities, Inc. 42nd Annual Health Care Conference
AMAG Submits Supplemental New Drug Application to FDA for Makena® (Hydroxyprogesterone Caproate Injection) Auto-Injector for Subcutaneous Use
Antares Pharma Announces Poster Presentation of Quickshot Testosterone Data at the Endocrine Society Annual Meeting
Antares Pharma to Report Fourth Quarter and Full Year 2016 Financial and Operating Results and Host Webcast and Conference Call

EWING, N.J., March 06, 2017 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) today announced it will release its fourth quarter and full year 2016 financial results and recent operating progress before the market opens on Tuesday, March 14, 2017.  Management will host a webcast and conference call at 8:30 a.m. ET (Eastern Time) on March 14, 2017 to discuss the results.
Interested parties may participate in the conference call by dialing 1-888-542-0999 (U.S.) or 1-719-325-2473 (international) and entering access code 9686901.  We encourage interested parties to dial into the conference call at least 10 minutes prior to the scheduled start time.  A replay of the conference call will be available from 11:30 a.m. ET on Tuesday, March 14, 2017, through 11:30 a.m. ET on Thursday, April 13, 2017 by dialing 1-888-203-1112 (U.S.) or 1-719-457-0820 (international), and entering the access code 9686901.  An audio webcast and archive of the conference call will also be available under the investor information section of the Antares Website at www.antarespharma.com. About Antares Pharma Antares Pharma focuses on self-administered parenteral pharmaceutical products. The Company’s product, OTREXUP® (methotrexate) injection for subcutaneous use, is approved in the U.S. for the treatment of adults with severe active rheumatoid arthritis, children with active polyarticular juvenile idiopathic arthritis and adults with severe recalcitrant psoriasis. The Company’s product Sumatriptan Injection USP, is approved in the U.S. for the acute treatment of migraine and cluster headache and is distributed by Teva Pharmaceutical Industries, Ltd. (Teva).    Antares Pharma is also developing QuickShot® Testosterone for testosterone replacement therapy and has filed a New Drug Application with the Food and Drug Administration. The Company's technology platforms include VIBEX® disposable auto injectors, disposable multi-use pen injectors and reusable needle-free injectors. Antares Pharma has license, development and supply agreements with Teva that include VIBEX® epinephrine, exenatide multi-dose pen, and teriparatide multi-dose pen.  Our reusable needle-free injector for use with human growth hormone (hGH) is sold worldwide by Ferring B.V.  The Company is also working with AMAG Pharmaceuticals on a subcutaneous method for administering Makena, a progesterone product indicated for use in lowering the risk of pre-term birth.  For more information, visit www.antarespharma.com. SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described.  Factors that may cause such differences include, but are not limited to: U.S. Food and Drug Administration (“FDA”) approval of the QST NDA and future market acceptance and revenue for QST; the outcome of the pending patent litigation between Teva Pharmaceutical Industries, Ltd. (Teva) and Eli Lilly and Company regarding the Teriparatide multi-dose pen; FDA action with respect to Teva’s Abbreviated New Drug Application (“ANDA”) for the Teriparatide multi-dose pen and the timing and approval, if any, by the FDA of the same; Teva’s ability to adequately and timely respond to the Complete Response Letter received from the FDA for the VIBEX® epinephrine pen ANDA and approval by the FDA of the same, the timing and therapeutic equivalence rating thereof, and any future purchase orders and revenue pre or post FDA approval; Teva’s ability to successfully commercialize VIBEX® Sumatriptan Injection USP and the amount of revenue from the same; FDA action with respect to Teva’s ANDA filed for the Exenatide pen and future revenue from the same; continued growth of prescriptions and sales of OTREXUP®;  the timing and results of the development project with AMAG Pharmaceuticals for an auto injector for Makena; the timing and results of research projects, clinical trials,  and product candidates in development; actions by the FDA or other regulatory agencies with the respect to the Company’s products or product candidates of its partners; continued growth in product, development, licensing and royalty revenue; the Company’s ability to obtain financial and other resources for its research, development, clinical, and commercial activities and other statements regarding matters that are not historical facts, and involve predictions. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, achievements or prospects to be materially different from any future results, performance, achievements or prospects expressed in or implied by such forward-looking statements. In some cases you can identify forward-looking statements by terminology such as ''may'', ''will'', ''should'', ''would'', ''expect'', ''intend'', ''plan'', ''anticipate'', ''believe'', ''estimate'', ''predict'', ''potential'', ''seem'', ''seek'', ''future'', ''continue'', or ''appear'' or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2015, and in the Company's other periodic reports and filings with the Securities and Exchange Commission.  The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. All forward-looking statements are based on information currently available to the Company on the date hereof, and the Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this press release, except as required by law.
Contacts:
Jack Howarth
Vice President, Corporate Affairs
609-359-3016
[email protected]

Read more...

Ratios

vs
industry
vs
history
PB Ratio 11.86
ATRS's PB Ratio is ranked lower than
94% of the 179 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.29 vs. ATRS: 11.86 )
Ranked among companies with meaningful PB Ratio only.
ATRS' s PB Ratio Range Over the Past 10 Years
Min: 1.83  Med: 7.7 Max: 24.29
Current: 11.86
1.83
24.29
PS Ratio 8.95
ATRS's PS Ratio is ranked lower than
85% of the 185 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.24 vs. ATRS: 8.95 )
Ranked among companies with meaningful PS Ratio only.
ATRS' s PS Ratio Range Over the Past 10 Years
Min: 2.16  Med: 10.85 Max: 30.56
Current: 8.95
2.16
30.56
EV-to-EBIT -25.78
ATRS's EV-to-EBIT is ranked lower than
99.99% of the 119 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 23.41 vs. ATRS: -25.78 )
Ranked among companies with meaningful EV-to-EBIT only.
ATRS' s EV-to-EBIT Range Over the Past 10 Years
Min: -121.9  Med: -10.9 Max: -1
Current: -25.78
-121.9
-1
EV-to-EBITDA -29.01
ATRS's EV-to-EBITDA is ranked lower than
99.99% of the 133 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 18.62 vs. ATRS: -29.01 )
Ranked among companies with meaningful EV-to-EBITDA only.
ATRS' s EV-to-EBITDA Range Over the Past 10 Years
Min: -126.8  Med: -11.6 Max: -1.1
Current: -29.01
-126.8
-1.1
Current Ratio 3.47
ATRS's Current Ratio is ranked lower than
61% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.69 vs. ATRS: 3.47 )
Ranked among companies with meaningful Current Ratio only.
ATRS' s Current Ratio Range Over the Past 10 Years
Min: 0.11  Med: 3.06 Max: 17.17
Current: 3.47
0.11
17.17
Quick Ratio 3.03
ATRS's Quick Ratio is ranked higher than
51% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.74 vs. ATRS: 3.03 )
Ranked among companies with meaningful Quick Ratio only.
ATRS' s Quick Ratio Range Over the Past 10 Years
Min: 0.09  Med: 2.78 Max: 16.5
Current: 3.03
0.09
16.5
Days Inventory 94.02
ATRS's Days Inventory is ranked higher than
77% of the 179 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 127.43 vs. ATRS: 94.02 )
Ranked among companies with meaningful Days Inventory only.
ATRS' s Days Inventory Range Over the Past 10 Years
Min: 11.13  Med: 33.79 Max: 200.11
Current: 94.02
11.13
200.11
Days Sales Outstanding 62.33
ATRS's Days Sales Outstanding is ranked higher than
61% of the 158 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 61.12 vs. ATRS: 62.33 )
Ranked among companies with meaningful Days Sales Outstanding only.
ATRS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 18.3  Med: 52.28 Max: 86.08
Current: 62.33
18.3
86.08
Days Payable 116.51
ATRS's Days Payable is ranked higher than
81% of the 151 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 50.69 vs. ATRS: 116.51 )
Ranked among companies with meaningful Days Payable only.
ATRS' s Days Payable Range Over the Past 10 Years
Min: 85.36  Med: 133.16 Max: 380
Current: 116.51
85.36
380

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -6.40
ATRS's 3-Year Average Share Buyback Ratio is ranked lower than
59% of the 128 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -4.00 vs. ATRS: -6.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ATRS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -140.2  Med: -16 Max: -0.7
Current: -6.4
-140.2
-0.7

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 23.54
ATRS's Price-to-Net-Current-Asset-Value is ranked lower than
88% of the 118 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.23 vs. ATRS: 23.54 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ATRS' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.89  Med: 8.97 Max: 54
Current: 23.54
0.89
54
Price-to-Tangible-Book 12.80
ATRS's Price-to-Tangible-Book is ranked lower than
87% of the 155 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.71 vs. ATRS: 12.80 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ATRS' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.62  Med: 7.37 Max: 1000
Current: 12.8
0.62
1000
Price-to-Median-PS-Value 0.82
ATRS's Price-to-Median-PS-Value is ranked higher than
71% of the 171 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.12 vs. ATRS: 0.82 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ATRS' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.09  Med: 0.94 Max: 5.56
Current: 0.82
0.09
5.56
Earnings Yield (Greenblatt) % -3.88
ATRS's Earnings Yield (Greenblatt) % is ranked lower than
75% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.70 vs. ATRS: -3.88 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ATRS' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -95.5  Med: -9.1 Max: -0.8
Current: -3.88
-95.5
-0.8

More Statistics

Revenue (TTM) (Mil) $53.10
EPS (TTM) $ -0.12
Beta0.38
Short Percentage of Float4.88%
52-Week Range $1.03 - 3.37
Shares Outstanding (Mil)156.41

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 51 91 163
EPS ($) -0.13 -0.09 1.08
EPS without NRI ($) -0.13 -0.09 1.08
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for ATRS

Headlines

Articles On GuruFocus.com
Antares Pharma to Report Second Quarter 2017 Financial and Operating Results and Host Webcast and Co Aug 01 2017 
Antares Pharma Announces Debt Financing From Hercules Capital Jun 07 2017 
Antares Pharma to Present at the Jefferies 2017 Healthcare Conference Jun 01 2017 
Antares Pharma Announces Poster Presentation at the American Urological Association Annual Meeting May 16 2017 
Antares Pharma Reports First Quarter 2017 Operating and Financial Results May 09 2017 
Antares Pharma to Report First Quarter 2017 Financial and Operating Results and Host Webcast and Con May 02 2017 
Antares Pharma to Present at the Deutsche Bank Securities, Inc. 42nd Annual Health Care Conference Apr 27 2017 
AMAG Submits Supplemental New Drug Application to FDA for Makena® (Hydroxyprogesterone Caproate I Apr 17 2017 
Antares Pharma Announces Poster Presentation of Quickshot Testosterone Data at the Endocrine Society Apr 03 2017 
Antares Pharma to Report Fourth Quarter and Full Year 2016 Financial and Operating Results and Host Mar 06 2017 

More From Other Websites
ATRS: Milestones Continue to Align for Multiple 2018 Launches Aug 14 2017
Edited Transcript of ATRS earnings conference call or presentation 8-Aug-17 12:30pm GMT Aug 13 2017
Antares Pharma, Inc. breached its 50 day moving average in a Bearish Manner : ATRS-US : August 10,... Aug 10 2017
Antares Pharma reports 2Q loss Aug 08 2017
Antares Pharma Reports Second Quarter 2017 Operating And Financial Results Aug 08 2017
Antares Pharma to Report Second Quarter 2017 Financial and Operating Results and Host Webcast and... Aug 01 2017
ETFs with exposure to Antares Pharma, Inc. : July 7, 2017 Jul 07 2017
ETFs with exposure to Antares Pharma, Inc. : June 26, 2017 Jun 26 2017
AMAG Announces U.S. FDA Filing Acceptance of Supplemental New Drug Application for Makena®... Jun 26 2017
Today's Research Reports on Stocks to Watch: Juno Therapeutics and Antares Pharma Jun 26 2017
Antares Pharma, Inc. :ATRS-US: Earnings Analysis: Q1, 2017 By the Numbers : June 14, 2017 Jun 14 2017
Antares Pharma, Inc. – Value Analysis (NASDAQ:ATRS) : June 13, 2017 Jun 13 2017
Antares Pharma, Inc. breached its 50 day moving average in a Bullish Manner : ATRS-US : June 12,... Jun 12 2017
Edited Transcript of ATRS earnings conference call or presentation 9-May-17 12:30pm GMT Jun 08 2017
Antares Pharma Announces Debt Financing From Hercules Capital Jun 07 2017
Antares Pharma to Present at the Jefferies 2017 Healthcare Conference Jun 01 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}